Jane Huang - Aug 31, 2021 Form 4 Insider Report for BeiGene, Ltd. (BGNE)

Role
CMO, Hematology
Signature
/s/ Qing Nian, as Attorney-in-Fact
Stock symbol
BGNE
Transactions as of
Aug 31, 2021
Transactions value $
-$346,621
Form type
4
Date filed
9/2/2021, 08:39 PM
Previous filing
Jul 19, 2021
Next filing
Sep 15, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BGNE Ordinary Shares Award $0 +7.16K +2.4% $0.00 306K Aug 31, 2021 Direct F1
transaction BGNE Ordinary Shares Award $0 +7.12K +2.33% $0.00 313K Sep 1, 2021 Direct F1
transaction BGNE American Depositary Shares Award $0 +542 $0.00 542 Aug 31, 2021 Direct F1, F2
transaction BGNE American Depositary Shares Sale -$168K -542 -100% $310.53 0 Sep 1, 2021 Direct F2, F3
transaction BGNE American Depositary Shares Award $0 +545 $0.00 545 Sep 1, 2021 Direct F1, F2
transaction BGNE American Depositary Shares Sale -$178K -545 -100% $327.18 0 Sep 2, 2021 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Vesting of a portion of a performance-based restricted share unit award upon satisfaction of performance conditions.
F2 Each American Depositary Share represents 13 Ordinary Shares.
F3 The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a performance-based restricted share unit award previously granted to the Reporting Person.